Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Breakfree-SLE: CC-97540 CD19 CAR T cells in active systemic lupus erythematosus
2024-519278-37-00Phase 2Suspended
- Sponsor
- Celgene Corporation
- Start
- Oct 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 16
01
Overview
Phase 2, open-label, single-arm trial of BMS-986353 in systemic lupus erythematosus (SLE) and lupus nephritis (LN), sponsored by Celgene Corporation. Primary endpoint: Drug-free DORIS remission. Started Oct 2025; status: suspended.
02
Drugs
BMS-986353
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on 2024-519278-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519278-37-00.